GuidelineBlood2014
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.
Guideline in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 264 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
264 citing papers in PubMed, 1 synthesis or guideline pooled it, 581 citations in OpenAlex.
- Radiological assessment of extremity bone involvement in Erdheim-Chester disease: a systematic review of case reports.Skeletal radiology · 2025Pooled it
- Trial
- Prognostic factors of Erdheim-Chester disease: a nationwide survey in Japan.Haematologica · 2018Trial
- Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.JAMA oncology · 2018Trial
- Dabrafenib plus trametinib in BRAF V600E-mutant Erdheim-Chester disease: a case series including CNS involvement.International journal of hematology · 2026Article
- Extranodal Rosai-Dorfman disease with bilateral renal involvement: A diagnostic challenge.Radiology case reports · 2026Article
- Histiocytosis development and clinical variation through the lens of genomics.The Journal of pathology · 2026Review
- Erdheim-Chester Disease with Breast and Axillary Involvement Diagnosed by Ultrasound-Guided Biopsy: A Case Report and Literature Review.Journal of clinical medicine · 2026Article
- International Olympic Committee Sport Mental Health Assessment Tool 2 (IOC SMHAT2): development, content validity and feasibility.British journal of sports medicine · 2026Article
- Erdheim-Chester disease presenting as complete heart block: A case report.HeartRhythm case reports · 2026Article
- Not just two roads down: a multimodality radiologic-pathologic review of ureteral diseases.Abdominal radiology (New York) · 2026Review
- Cardiovascular Involvement in Erdheim-Chester Disease Presenting as Pericardial Tamponade: A Case Report and Multimodality Imaging Review.Journal of clinical medicine · 2026Review
- Rosai-Dorfman disease withOxford medical case reports · 2026Article
- Origin, diagnosis and treatment of periocular Histiocytic disorders- state-of-the-art review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
- Article
- Case Report: Erdheim-Chester disease presenting as abdominal cocoon syndrome.Frontiers in immunology · 2026Article
- Vertebral involvement in Erdheim-Chester disease: a case report of non-BRAF-driven diagnosis and treatment challenges.Frontiers in oncology · 2026Article
- Perioperative multidisciplinary rescue of a patient with Erdheim - Chester disease and multi-system involvement: a case report.Frontiers in medicine · 2026Article
- Erdheim-Chester Disease Diagnosed by a Pericardial Fluid Cell Block Analysis.Internal medicine (Tokyo, Japan) · 2025Article
- Article
204 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
17 authors at 11 institutions in 3 countries.
Funding
Abstract
Erdheim-Chester disease (ECD) is a rare, non-Langerhans histiocytosis. Recent findings suggest that ECD is a clonal disorder, marked by recurrent BRAFV600E mutations in >50% of patients, in which chronic uncontrolled inflammation is an important mediator of disease pathogenesis. Although ∼500 to 550 cases have been described in the literature to date, increased physician awareness has driven a dramatic increase in ECD diagnoses over the last decade. ECD frequently involves multiple organ systems and has historically lacked effective therapies. Given the protean clinical manifestations and the lack of a consensus-derived approach for the management of ECD, we provide here the first multidisciplinary consensus guidelines for the clinical management of ECD. These recommendations were outlined at the First International Medical Symposium for ECD, comprised of a comprehensive group of international academicians with expertise in the pathophysiology and therapy of ECD. Detailed recommendations on the initial clinical, laboratory, and radiographic assessment of ECD patients are presented in addition to treatment recommendations based on critical appraisal of the literature and clinical experience. These formalized consensus descriptions will hopefully facilitate ongoing and future research efforts in this disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.